Dyadic International (DYAI) Cash from Investing Activities Growth (3y) (2021 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Cash from Investing Activities Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn | -39.19% |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | -177.73% |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn | 46.78% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 66.14% |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn | -44.69% |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn | -246.81% |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn | -72.08% |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 18.24 Mn | 10.27 Mn | - | -22.94% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -22.94% |
| Dec 31, 2025 | -8.84% |
| Sep 30, 2025 | 27.47% |
| Jun 30, 2025 | 5.96% |
| Mar 31, 2025 | 43.02% |
| Dec 31, 2024 | -34.52% |
| Sep 30, 2024 | -26.05% |
| Jun 30, 2024 | -26.00% |
| Mar 31, 2024 | 95.16% |
| Dec 31, 2023 | -3.67% |
| Sep 30, 2023 | -32.47% |
| Jun 30, 2023 | -49.93% |
| Mar 31, 2023 | 17.69% |
| Dec 31, 2022 | -22.74% |
| Sep 30, 2022 | -44.82% |
| Jun 30, 2022 | -36.64% |
| Mar 31, 2022 | -29.53% |
| Dec 31, 2021 | 33.08% |
| Sep 30, 2021 | 48.12% |
| Jun 30, 2021 | 2,553.80% |